Laboratory Performance of the DopaFuse® Delivery System
Objective: SynAgile has developed the DopaFuse Delivery System to noninvasively and continuously administer levodopa/carbidopa (LD/CD) into the mouths of patients with Parkinson’s Disease (PD). The…Olfactory Hallucinations Induced by Pramipexole Treatment in Parkinson’s Disease
Objective: In the treatment of Parkinson’s disease, dopamine agonists are among the preferred treatment options, particularly in the treatment of young Parkinson’s patients. The known…Formulations and evaluations of Intranasal Nose to Brain Delivery of Curcumin with resveratrol Nanoparticle for treatment of Parkisonism
Objective: Parkinson’s disease (PD) is a common neurodegenerative disease characterized by motor symptoms of tremor, rigidity, bradykinesia, and postural instability. Growing evidence indicates that resveratrol…Efficacy of opicapone in Parkinson’s disease patients according to baseline pramipexole use: a post-hoc analysis from combined BIPARK-I and II.
Objective: To evaluate opicapone’s (OPC) efficacy in levodopa-treated Parkinson’s Disease (PD) patients with or without concurrent pramipexole use (CPU). Background: OPC, a once-daily COMT inhibitor,…Path to Prevention (P2P) – Developing a Prodromal PD Progression Biomarker Program
Objective: The overall objective of the Path to Prevention (P2P) initiative is to identify clinical, imaging, and biologic markers of progression during the prodromal phase…A pilot study of the feasibility and effects of table tennis training in Parkinson’s Disease
Objective: To investigate the feasibility and effects of table tennis training on balance control and physical function in individuals with Parkinson’s disease (PD). Background: Postural…Unilateral delivery of cell-based therapy to the putamen and substantia nigra in patients with Parkinson’s disease who have an existing DBS system
Objective: Evaluate the safety and feasibility of unilateral cell-based therapy delivery to the putamen and substantia nigra in patients with Parkinson’s disease (PD) undergoing deep…Safety of Bone marrow-derived Allogeneic Mesenchymal Stem Cells in Parkinson’s disease Patients
Objective: Prove safety and tolerability of allogeneic mesenchymal stem cells (MSC) purified from bone marrow derived from a healthy adult and delivered intravenously in escalated…Short term use of bromocriptine for treatment of Parkinson’s disease during pregnancy
Objective: Few reports describe experience with treatment of Parkinson's disease [PD] during pregnancy. About 5% of the population with PD are young onset (onset prior…Impact of oral COMT-inhibitors on gut microbiota and biologically active microbial metabolites in patients with Parkinson’s Disease
Objective: To investigate if we were able to reproduce our previous findings in an independent patient cohort and whether such a correlation also exists in…
- « Previous Page
- 1
- …
- 108
- 109
- 110
- 111
- 112
- …
- 217
- Next Page »